ArticleArchives of osteoporosis2025
Renal function predicts 12-month response to romosozumab readministration after denosumab in women with osteoporosis.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lower estimated glomerular filtration rate (eGFR) independently predicted greater increases in lumbar spine and total hip bone mineral density after romosozumab readministration following denosumab. An eGFR cutoff of 54 mL/min/1.73 m PURPOSE: This study investigated whether renal function is an independent predictor of bone mineral density (BMD) increase during romosozumab readministration after denosumab in women with osteoporosis.
methodsA multicenter study was conducted involving 31 Japanese women with osteoporosis who received romosozumab readministration between March 2019 and July 2024 following initial 12-month romosozumab treatment and sequential denosumab therapy. The estimated glomerular filtration rate (eGFR) at baseline and percent changes in lumbar spine (LS) and total hip (TH) BMD from baseline to 12 months were investigated. Multivariate regression analyses were performed to assess the association between renal function and BMD, adjusting for all previously reported potential confounders, including secondary osteoporosis, age, denosumab duration, BMD, and bone turnover makers. Receiver operating characteristic (ROC) curves were used to determine eGFR cutoff values predicting ≥ 3% BMD increase (i.e., treatment response).
resultsApproximately 38.7% and 19.4% of patients achieved ≥ 3% increase in LS and TH BMD at 12 months, respectively. Lower eGFR was significantly associated with greater LS (adjusted β = - 0.14, 95% confidence interval [CI] - 0.27 to - 0.01) and TH BMD increases (adjusted β = - 0.10, 95% CI - 0.18 to - 0.01). The optimal eGFR cutoff value predicting LS or TH response was 54.1 mL/min/1.73 m
conclusionLower baseline eGFR was an independent predictor of greater LS or TH BMD response to romosozumab readministration after denosumab, with an optimal cutoff value of 54 mL/min/1.73 m
Indexed as
Identifiers
41364391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.